Appeals Court Revives Teva Patent Lawsuit Against Eli Lilly Over Forteo

Key Facts

In a move highlighting the complex legal landscape of the pharmaceutical sector, a U.S. appeals court has revived a lawsuit filed by Teva Pharmaceuticals against Eli Lilly. The dispute centers on patents for the osteoporosis drug Forteo, with the court overturning a previous ruling that had dismissed Teva's claims. This decision allows Teva to proceed with its allegations of patent infringement regarding the manufacturing or distribution of the treatment.

This development comes as Eli Lilly navigates intense competition in the specialty drug market, having recently seen strong revenue growth from blockbusters like Mounjaro, though the revived Forteo litigation introduces renewed legal risks and potential damages. Compared to peers like Pfizer and Amgen, patent protection remains the primary driver of profit margins in the industry, as intellectual property disputes frequently dictate long-term valuation shifts per market data.

Regarding market performance, LLY stood at $1,191.23 (July 13, 2026), while TEVA was priced at $32.95 (July 10, 2026). Investors are now monitoring further legal filings that could impact the cash flow outlook for both firms, particularly as the broader healthcare sector remains sensitive to intellectual property rulings and upcoming regulatory catalysts.